Exendin-4 for Parkinson's disease
Félipe Esparza Salazar, Alma R. Lezama Toledo, Germán Rivera-Monroy, Cesario V. Borlongan
Abstract
This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.
Topics & Concepts
ExenatideParkinson's diseaseAgonistDiseaseMedicineGlucagon-like peptide 1 receptorClinical trialNeuroscienceReceptorInternal medicineType 2 diabetesDiabetes mellitusEndocrinologyPsychologyDiabetes Treatment and ManagementParkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatments